Latest News in the pharma Industry

Research & Development

Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

30 Dec 2015

Second of two planned trials combining Adcetris and Opdivo under clinical collaboration agreement.

Read more 
Actelion receices FDA approval of Uptravi  for the treatment of pulmonary arterial hypertension

Actelion receices FDA approval of Uptravi for the treatment of pulmonary arterial hypertension

30 Dec 2015

Uptravi will be made available to patients in the US in early January 2016.

Read more 
Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin

Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin

29 Dec 2015

sugardown reduces total glycemic index including fructose by up to 28% and insulin by up to 18%.

Read more 
Stellar Biotechnologies presents research on nanofiltration development at PepTalk Conference

Stellar Biotechnologies presents research on nanofiltration development at PepTalk Conference

26 Jan 2016

The presentation reported data from the company's development and validation of filtration methods for the removal of viruses during manufacturing processes of KLH products.

Read more 
APAC multiple myeloma therapy market hit $1.7 billion in 2014 and will add $1.1 billion by 2021

APAC multiple myeloma therapy market hit $1.7 billion in 2014 and will add $1.1 billion by 2021

23 Dec 2015

Emergence of novel therapeutics and minimal generic competition in China, Japan and Australia will drive APAC multiple myeloma market growth to 2021, says GBI Research.

Read more 
Merck and Pfizer advance clinical development program with two additional phase III trials of avelumab

Merck and Pfizer advance clinical development program with two additional phase III trials of avelumab

22 Dec 2015

Merck-Pfizer Alliance achieves 2015 goal of initiating six pivotal trials with JAVELIN Ovarian 200 and JAVELIN Bladder 100 trials.

Read more 
Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with NSCLC

Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with NSCLC

22 Dec 2015

FDA designation reinforces potential for BI 1482694 to become a new treatment option for patients with EGFR mutation-positive lung cancer with a T790M mutation.

Read more 
Bayer and CRISPR Therapeutics join forces to discover, develop and commercialize potential cures for serious genetic diseases

Bayer and CRISPR Therapeutics join forces to discover, develop and commercialize potential cures for serious genetic diseases

21 Dec 2015

Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit.

Read more 
Increased investment spurs advances in gene therapy

Increased investment spurs advances in gene therapy

18 Dec 2015

The success of approved products for rare illnesses has opened the door for gene-based treatments of more prevalent diseases, finds Frost & Sullivan.

Read more 
FDA Draft Guidance: Safety Assessment for IND Safety Reporting

FDA Draft Guidance: Safety Assessment for IND Safety Reporting

18 Dec 2015

The FDA has published draft guidance for sponsors of investigational new drug application (IND) studies with recommendations for identifying and evaluating important safety information that must be submitted to FDA and all participating investigators u...

Read more 
Future obesity drugs must provide improved efficacy and safety, says GBI Research

Future obesity drugs must provide improved efficacy and safety, says GBI Research

17 Dec 2015

A highly innovative and diverse pipeline of 248 products in active development is set to tackle the ever-encroaching obesity crisis.

Read more 
WuXi and AstraZeneca form strategic alliance to expedite development of AstraZeneca's innovative biologics portfolio in China

WuXi and AstraZeneca form strategic alliance to expedite development of AstraZeneca's innovative biologics portfolio in China

16 Dec 2015

Alliance will bring cutting-edge research and technical capability for biologics to China with the aim of addressing unmet patient needs in AstraZeneca's main therapy areas of respiratory, inflammation and autoimmunity; cardiovascular and metabolic dis...

Read more